| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Dermata Therapeutics, Inc. have bought $0 and sold $0 worth of Dermata Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Dermata Therapeutics, Inc. have bought $1.05M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 152,857 shares for transaction amount of $1.05M was made by PROEHL GERALD T (President, CEO and Chairman) on 2021‑08‑16.
| PROEHL GERALD T | President, CEO and Chairman | 152857 22.4276% | $184,956.97 | 1 | 0 | <0.0001% |
$1,848,072 | 66 | -14.67% | $1.87M | |
$53,490,060 | 55 | 19.35% | $3.28M | |
$1,138,733 | 28 | -4.94% | $3.2M | |
$337,688 | 19 | -33.30% | $2.18M | |
$8,079,884 | 14 | -43.20% | $1.36M | |
$105,917 | 11 | -28.06% | $2.56M | |
$389,864 | 11 | 12.52% | $2.71M | |
$82,890 | 11 | -16.74% | $1.77M | |
$18,269 | 10 | -21.15% | $2.79M | |
$126,023 | 10 | -66.17% | $1.66M | |
$245,000 | 7 | -62.00% | $2.27M | |
$7,268,979 | 7 | -48.44% | $2.41M | |
$70,828 | 6 | -57.96% | $1.67M | |
$726,438 | 4 | -72.85% | $1.28M | |
$553,551 | 4 | -74.30% | $573,040.00 | |
Dermata Therapeutics, Inc. (DRMA) | $1,049,630 | 1 | -74.91% | $824,684.00 |
$19,863 | 1 | 144.27% | $968,228.00 | |
$23,454 | 1 | -99.16% | $9,338.00 | |
$9,963 | 1 | -14.25% | $2.29M |
| Increased Positions | 5 | +100% | 25,124 | +27.24% |
| Decreased Positions | 2 | -40% | 90,464 | -98.08% |
| New Positions | 3 | New | 20,098 | New |
| Sold Out Positions | <1 | Sold Out | 81,654 | Sold Out |
| Total Postitions | 8 | +60% | 26,892 | -70.84% |
| Armistice Capital, Llc | $178.00 | 8.16% | 81,654 | +49,436 | +153.44% | 2025-09-30 |
| Ubs Group Ag | $22.00 | 1.01% | 10,047 | +951 | +10.46% | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $1.00 | 0.04% | 426 | -106 | -19.93% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $0 | 0.01% | 101 | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $0 | 0% | 4 | +<1 | +33.33% | 2025-09-30 |
| Citigroup Inc | $0 | 0% | 0 | -6 | Sold Out | 2025-09-30 |
| Two Sigma Securities, Llc | $0 | 0% | 0 | -1,472 | Sold Out | 2025-09-30 |
| Boothbay Fund Management, Llc | $0 | 0% | 0 | -12,000 | Sold Out | 2025-09-30 |
| Geode Capital Management, Llc | $0 | 0% | 0 | -2,739 | Sold Out | 2025-09-30 |
| Jones Financial Companies Lllp | $0 | 0% | 0 | -1,200 | Sold Out | 2025-09-30 |